Consequences of Termination of this Agreement. If this Agreement is terminated by a Party in accordance with this ARTICLE 10 in its entirety or on a Product-by-Product basis at any time and for any reason, the following terms will apply to any such termination, but only to the extent of any such termination (i.e., in total or on a Product-by-Product basis):
Consequences of Termination of this Agreement. (a) On termination of this agreement, the Authorised Representative will:
Consequences of Termination of this Agreement. Upon termination of this Agreement, all remaining records and materials in a Party's possession or control containing the other Party's Confidential Information and to which the former Party does not retain rights hereunder shall promptly be returned.
Consequences of Termination of this Agreement. If this Agreement is terminated by a Party in accordance with Sections 10.3.2, 10.3.3, 10.3.4, 10.3.5, or 10.3.7, in each case, in its entirety at any time and for any reason, then the following terms will apply to any such termination:
Consequences of Termination of this Agreement. Upon termination of this Agreement under this Article 8.0, the following rights and obligations shall apply:
Consequences of Termination of this Agreement. 14.3.1. All rights and licenses granted under or pursuant to this Agreement by Quanterix are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, and foreign equivalents thereof (the “Bankruptcy Code”), licenses of right to “intellectual property” as defined under Section 61 of the U.S. Bankruptcy Code. The Parties agree that bioMérieux, as licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against Quanterix under the Bankruptcy Code, bioMérieux shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, which, if not already in the bioMérieux’s possession, shall be promptly delivered to it (a) upon any such commencement of a bankruptcy proceeding upon bioMérieux’s written request therefor, unless Quanterix elects to continue to perform all of its obligations under this Agreement, or (b) if not delivered under Section 14.3.1(a), following the rejection of this Agreement by or on behalf of Quanterix upon written request therefor by bioMérieux.
Consequences of Termination of this Agreement. (a) Termination by Roche at Will or by Prothena for Breach by Roche or Roche’s Insolvency. Upon termination by Roche at will under Section 16.2, or termination by Prothena for breach by Roche under Section 16.4 or for Roche’s insolvency under Section 16.5, the following shall apply:
Consequences of Termination of this Agreement. In the event of termination of the Agreement on the grounds set out in Clause 8.1 or 8.2 above, BANCO SANTANDER shall make such termination public by filing a price- sensitive information notice (hecho relevante) with the CNMV, and the Capital Increase will not be underwritten. In this event, the following consequences will occur, depending on the date of termination of the Agreement:
Consequences of Termination of this Agreement. 16.1 On termination under Clauses 15.1.1 to 15.1.9 inclusive EEM shall be entitled to recover from the Consultant all of the loss, damage and costs it suffers or incurs arising out of such termination including without prejudice to the generality of the foregoing:
Consequences of Termination of this Agreement. 15. Where this Agreement is terminated under Clause 14, that termination does not affect the operation of this Agreement and your liability to continue to indemnify us under the terms of this Agreement in respect of Policies issued prior to the termination, for any Insurance Claims made:
